Msp2 variation in Anaplasma phagocytophilum in vivo does not stimulate T cell immune responses or interferon-γ production

FEMS Immunology and Medical Microbiology

Volumn 49, Issue 3, 2007, Pages 374-386

  Choi, Kyoung Seong ^a,b   Scorpio, Diana G ^a   Barat, Nicole C ^a   Stephen Dumler, J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kyungpook National University   (South Korea)

Author keywords

Anaplasma phagocytophilum; Cellular immunity; Histopathology; Innate immunity; Mouse model; T lymphocyte

Indexed keywords

BACTERIAL PROTEIN; GAMMA INTERFERON; MAJOR SURFACE PROTEIN 2; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANAPLASMA PHAGOCYTOPHILUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEPATITIS; HISTOPATHOLOGY; IN VIVO STUDY; INOCULATION; LYMPHOCYTE PROLIFERATION; MITOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN CELL; STIMULATION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANAPLASMA PHAGOCYTOPHILUM; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENIC VARIATION; BACTERIAL OUTER MEMBRANE PROTEINS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EHRLICHIOSIS; HISTOCYTOCHEMISTRY; INTERFERON TYPE II; LIVER; LYMPHOCYTES; MICE; MICE, INBRED C57BL; RNA, BACTERIAL; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SPLEEN; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 33947236233     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00214.x     Document Type: Article

References (47)

1. Abbott JR, Palmer GH, Kegerreis KA, Hetrick PF, Howard CJ, Hope JC & Brown WC (2005) Rapid and long-term disappearance of CD4+ T lymphocyte responses specific for Anaplasma marginale major surface protein-2 (MSP2) in MSP2 vaccinates following challenge with live A. marginale. J Immunol 174: 6702-6715.
2. Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, McKenna DF, Nowakowski J, Munoz J & Dumler JS (1996) Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med 125: 904-908.
3. Akkoyunlu M & Fikrig E (2000) Gamma interferon dominates the murine cytokine response to the agent of human granulocytic ehrlichiosis and helps to control the degree of early rickettsemia. Infect Immun 68: 1827-1833.
4. Asanovich KM, Bakken JS, Madigan JE, Aguero-Rosenfeld M, Wormser GP & Dumler JS (1997) Antigenic diversity of granulocytic Ehrlichia isolates from humans in Wisconsin and New York and a horse in California. J Infect Dis 176: 1029-1034.
5. Bakken JS & Dumler JS (2000) Human granulocytic ehrlichiosis. Clin Infect Dis 31: 554-560.
6. Barbet AF, Yi J, Lundgren A,McEwen BR, Blouin EF & Kocan KM (2001) Antigenic variation of Anaplasma marginale: major surface protein 2 diversity during cyclic transmission between ticks and cattle. Infect Immun 69: 3057-3066.
7. Borjesson DL & Barthold SW (2002) The mouse as a model for investigation of human granulocytic ehrlichiosis: current knowledge and future directions. Comp Med 52: 403-413.
8. Brayton KA, Palmer GH, Lundgren A, Yi J & Barbet AF (2002) Antigenic variation of Anaplasma marginale msp2 occurs by combinatorial gene conversion. Mol Microbiol 43: 1151-1159.
9. Brown WC, Zhu D, Shkap V, McGuire TC, Blouin EF, Kocan KM & Palmer GH (1998) The repertoire of Anaplasma marginale antigens recognized by CD4(1) T-lymphocyte clones from protectively immunized cattle is diverse and includes major surface protein 2 (MSP-2) and MSP-3. Infect Immun 66: 5414-5422.
10. Brown WC, McGuire TC, Zhu D, Lewin HA, Sosnow J & Palmer GH (2001) Highly conserved regions of the immunodominant major surface protein 2 of the genogroup II ehrlichial pathogen Anaplasma marginale are rich in naturally derived CD4+ T lymphocyte epitopes that elicit strong recall responses. J Immunol 166: 1114-1124.
11. Brown WC, Brayton KA, Styer CM & Palmer GH (2003) The hypervariable region of Anaplasma marginale major surface protein 2 (MSP2) contains multiple immunodominant CD4+ T lymphocyte epitopes that elicit variant-specific proliferative and IFN-gamma responses in MSP2 vaccinates. J Immunol 170: 3790-3798.
12. Brown WC, Palmer GH, Brayton KA, Meeus PF, Barbet AF, Kegerreis KA & McGuire TC (2004) CD4+ T lymphocytes from Anaplasma marginale major surface protein 2 (MSP2) vaccinees recognize naturally processed epitopes conserved in MSP3. Infect Immun 72: 3688-3692.
13. Buitrago MI, Ijdo JW, Rinaudo P, Simon H, Copel J, Gadbaw J, Heimer R, Fikrig E & Bia FJ (1998) Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis 27: 213-215.
14. Bunnell JE, Trigiani ER, Srinivas SR & Dumler JS (1999) Development and distribution of pathologic lesions are related to immune status and tissue deposition of human granulocytic ehrlichiosis agent-infected cells in a murine model system. J Infect Dis 180: 546-550.
15. Caspersen K, Park JH, Patil S & Dumler JS (2002) Genetic variability and stability of Anaplasma phagocytophila msp2 (p44). Infect Immun 70: 1230-1234.
16. Choi KS, Scorpio DG & Dumler JS (2004) Anaplasma phagocytophilum ligation to toll-like receptor (TLR) 2, but not to TLR4, activates macrophages for nuclear factor-kappa B nuclear translocation. J Infect Dis 189: 1921-1925.
17. Dumler JS, Asanovich KM, Bakken JS, Richter P, Kimsey R & Madigan JE (1995) Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic Ehrlichia. J Clin Microbiol 33: 1098-1103.
18. Dumler JS, Choi KS, Garcia-Garcia JC, Barat NS, Scorpio DG, Garyu JW, Grab DJ & Bakken JS (2005) Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 11: 1828-1834.
19. Dunning Hotopp JC, Lin M, Madupu R et al. (2006) Comparative genomics of emerging human ehrlichiosis agents. PLoS Genet 2: e21.
20. French DM, Brown WC & Palmer GH (1999) Emergence of Anaplasma marginale antigenic variants during persistent rickettsemia. Infect Immun 67: 5834-5840.
21. Greig B, Asanovich KM, Armstrong PJ & Dumler JS (1996) Geographic, clinical, serologic, and molecular evidence of granulocytic ehrlichiosis, a likely zoonotic disease, in Minnesota and Wisconsin dogs. J Clin Microbiol 34: 44-48.
22. Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucleic Acids Symp Ser 41: 95-98.
23. IJdo JW, Zhang Y, Hodzic E, Magnarelli LA, Wilson ML, Telford SR III, Barthold SW & Fikrig E (1997) The early humoral response in human granulocytic ehrlichiosis. J Infect Dis 176: 687-692.
24. IJdo JW, Sun W, Zhang Y, Magnarelli LA & Fikrig E (1998) Cloning of the gene encoding the 44-kilodalton antigen of the agent of human granulocytic ehrlichiosis and characterization of the humoral response. Infect Immun 66: 3264-3269.
25. IJdo JW, Wu C, Telford SR III & Fikrig E (2002) Differential expression of the p44 gene family in the agent of human granulocytic ehrlichiosis. Infect Immun 70: 5295-5298.
26. Lepidi H, Bunnell JE, Martin ME, Madigan JE, Stuen S & Dumler JS (2000) Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg 62: 29-37.
27. Lin Q & Rikihisa Y (2005) Establishment of cloned Anaplasma phagocytophilum and analysis of p44 gene conversion within an Iinfected horse and infected SCID mice. Infect Immun 73: 5106-5114.
28. Lotric-Furlan S, Petrovec M, Avsic-Zupanc T & Strle F (2004) Comparison of patients fulfilling criteria for confirmed and probable human granulocytic ehrlichiosis. Scand J Infect Dis 36: 817-822.
29. Madigan JE (1993) Equine ehrlichiosis. Vet Clin North Am Equine Pract 9: 423-428.
30. Martin ME, Bunnell JE & Dumler JS (2000) Pathology, immunohistology, and cytokine responses in early phases of human granulocytic ehrlichiosis in a murine model. J Infect Dis 181: 374-378.
31. Martin ME, Caspersen K & Dumler JS (2001) Immunopathology and ehrlichial propagation are regulated by interferon-gamma and interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol 158: 1881-1888.
32. Murphy CI, Storey JR, Recchia J, Doros-Richert LA, Gingrich-Baker C, Munroe K, Bakken JS, Coughlin RT & Beltz GA (1998) Major antigenic proteins of the agent of human granulocytic ehrlichiosis are encoded by members of a multigene family. Infect Immun 66: 3711-3718.
33. Page RD (1996) TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 12: 357-358.
34. Palmer GH, Eid G, Barbet AF, McGuire TC & McElwain TF (1994) The immunoprotective Anaplasma marginale major surface protein 2 is encoded by a polymorphic multigene family. Infect Immun 62: 3808-3816.
35. Park J, Choi KS & Dumler JS (2003) Major surface protein 2 of Anaplasma phagocytophilum facilitates adherence to granulocytes. Infect Immun 71: 4018-4025.
36. Pusterla N, Madigan JE, Asanovich KM, Chae JS, Derock E, Leutenegger CM, Pusterla JB, Lutz H & Dumler JS (2000) Experimental inoculation with human granulocytic Ehrlichia agent derived from high- and low-passage cell culture in horses. J Clin Microbiol 38: 1276-1278.
37. Scorpio DG, Caspersen K, Ogata H, Park J & Dumler JS (2004) Restricted changes in major surface protein-2 (msp2) transcription after prolonged in vitro passage of Anaplasma phagocytophilum. BMC Microbiol 4: 1.
38. Scorpio DG, von Loewenich FD, Gobel H, Bogdan C & Dumler JS (2006) Innate immune response to Anaplasma phagocytophilum contributes to hepatic injury. Clin Vaccine Immunol 13: 806-809.
39. Sun W, IJdo JW, Telford SR III, Hodzic E, Zhang Y, Barthold SW & Fikrig E (1997) Immunization against the agent of human granulocytic ehrlichiosis in a murine model. J Clin Invest 100: 3014-3018.
40. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F & Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
41. von Loewenich FD, Scorpio DG, Reischl U, Dumler JS & Bogdan C (2004) Frontline: control of Anaplasma phagocytophilum, an obligate intracellular pathogen, in the absence of inducible nitric oxide synthase, phagocyte NADPH oxidase, tumor necrosis factor, Toll-like receptor (TLR)2 and TLR4, or the TLR adaptor molecule MyD88. Eur J Immunol 34: 1789-1797.
42. Wang X, Rikihisa Y, Lai TH, Kumagai Y, Zhi N & Reed SM (2004) Rapid sequential changeover of expressed p44 genes during the acute phase of Anaplasma phagocytophilum infection in horses. Infect Immun 72: 6852-6859.
43. Wemme H, Pfeifer S, Heck R & Muller-Quernheim J (1992) Measurement of lymphocyte proliferation: critical analysis of radioactive and photometric methods. Immunobiology 185: 78-89.
44. Zhi N, Rikihisa Y, Kim HY,Wormser GP & Horowitz HW (1997) Comparison of major antigenic proteins of six strains of the human granulocytic ehrlichiosis agent by Western immunoblot analysis. J Clin Microbiol 35: 2606-2611.
45. Zhi N, Ohashi N, Rikihisa Y, Horowitz HW, Wormser GP & Hechemy K (1998) Cloning and expression of the 44-kilodalton major outer membrane protein gene of the human granulocytic ehrlichiosis agent and application of the recombinant protein to serodiagnosis. J Clin Microbiol 36: 1666-1673.
46. Zhi N, Ohashi N & Rikihisa Y (1999) Multiple p44 genes encoding major outer membrane proteins are expressed in the human granulocytic ehrlichiosis agent. J Biol Chem 274: 17828-17836.
47. Zhi N, Ohashi N, Tajima T, Mott J, Stich RW, Grover D, Telford SR III, Lin Q & Rikihisa Y (2002) Transcript heterogeneity of the p44 multigene family in a human granulocytic ehrlichiosis agent transmitted by ticks. Infect Immun 70: 1175-1184.